1. The mechanism behind activation of the Nod-like receptor family protein 3 inflammasome in Parkinson’s disease
- Author
-
Jin-Ni Fang, Fei-Fei Hua, Jing Wang, Anmu Xie, Xiaona Zhang, Zeng-Qiang Yuan, and Jing-Yang Han
- Subjects
medicine.drug_class ,Receptor expression ,Parkinson's disease ,Substantia nigra ,atp ,neurodegenerative disorder ,neuroinflammation ,neuroinflammatory response ,nlrp3 ,p2x4 ,parkinson’s disease ,Developmental Neuroscience ,NLRP3 ,medicine ,RC346-429 ,Neuroinflammation ,integumentary system ,business.industry ,Pars compacta ,Neurodegeneration ,NOD-like receptor ,Inflammasome ,medicine.disease ,Receptor antagonist ,ATP ,P2X4 ,Cancer research ,Neurology. Diseases of the nervous system ,business ,medicine.drug ,Research Article - Abstract
Previous studies have shown that the ATP-P2X4 receptor signaling pathway mediates the activation of the Nod-like receptor family protein 3 (NLRP3) inflammasome. The NLRP3 inflammasome may promote renal interstitial inflammation in diabetic nephropathy. As inflammation also plays an important role in the pathogenesis of Parkinson's disease, we hypothesized that the ATP-P2X4 receptor signaling pathway may activate the NLRP3 inflammasome in Parkinson's disease. A male rat model of Parkinson's disease was induced by stereotactic injection of 6-hydroxydopamine into the pars compacta of the substantia nigra. The P2X4 receptor and the NLRP3 inflammasome (interleukin-1β and interleukin-18) were activated. Intracerebroventricular injection of the selective P2X4 receptor antagonist 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD) or knockdown of P2X4 receptor expression by siRNA inhibited the activation of the NLRP3 inflammasome and alleviated dopaminergic neurodegeneration and neuroinflammation. Our results suggest that the ATP-P2X4 receptor signaling pathway mediates NLRP3 inflammasome activation, dopaminergic neurodegeneration, and dopamine levels. These findings reveal a novel role of the ATP-P2X4 axis in the molecular mechanisms underlying Parkinson's disease, thus providing a new target for treatment. This study was approved by the Animal Ethics Committee of Qingdao University, China, on March 5, 2015 (approval No. QYFYWZLL 26119).
- Published
- 2022